Caca Biljanovska N, V'lckova Laskoska M
Department of Dermatology, School of Medicine, Ss. Cyril and Methodius University of Skopje, Skopje, R. Macedonia.
Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2013;34(1):143-53.
Psoriasis is a chronic, systemic T-cell mediated autoimmune skin disease, potentially associated with arthritis. The new understanding of immunopathogenesis and inflammatory cytokine pathways was actually the rationale for developing and introducing biological drugs in the treatment of moderate to severe psoriasis and psoriatic arthritis. Different from the traditional systemic drugs that impact the entire immune system, bio-logics target only specific points of the immune system. This review focuses on five biologics which target either T-cells (alefacept) or TNF-alpha (etanercept, adalimumab and infliximab) or interleukin IL-12/IL-23 (ustekinumab)--their efficacy, safety, patient monitoring and recommended dosage. The purpose of the treatment guidelines presented here is to provide a high standard of continuing care of psoriasis and psoriatic arthritis patients.
银屑病是一种慢性、全身性的由T细胞介导的自身免疫性皮肤病，可能与关节炎有关。对免疫发病机制和炎性细胞因子途径的新认识实际上是研发和引入生物药物治疗中度至重度银屑病及银屑病关节炎的理论依据。与影响整个免疫系统的传统全身性药物不同，生物制剂仅靶向免疫系统的特定靶点。本综述聚焦于五种生物制剂，它们分别靶向T细胞（阿法赛特）或肿瘤坏死因子-α（依那西普、阿达木单抗和英夫利昔单抗）或白细胞介素IL-12/IL-23（乌司奴单抗）——它们的疗效、安全性、患者监测及推荐剂量。此处给出的治疗指南旨在为银屑病和银屑病关节炎患者提供高标准的持续护理。
